| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
T-Helper Cells CD4/CD8
MessageSendout, Mayo test code: TCD4
Test Code
LAB343
Alias/See Also
CD4 Count
CD8 Count, Flow Cytometry
Helper Suppressor Ratio
Immune Competence
Immune Status-Flow Cytometry
Immunodeficiency Panel-Flow Cytometry
Quantitative CD4 and CD8
T Cell
T Cells
T Lymphocyte Surface Markers
T-Cell Surface Markers
T-Cells
T-Helper/T-Suppressor-Flow Cytometry
T4/T8 Helper Suppressor Ratio
AIDS (Acquired Immune Deficiency Syndrome)
TCD4
CD8 Count, Flow Cytometry
Helper Suppressor Ratio
Immune Competence
Immune Status-Flow Cytometry
Immunodeficiency Panel-Flow Cytometry
Quantitative CD4 and CD8
T Cell
T Cells
T Lymphocyte Surface Markers
T-Cell Surface Markers
T-Cells
T-Helper/T-Suppressor-Flow Cytometry
T4/T8 Helper Suppressor Ratio
AIDS (Acquired Immune Deficiency Syndrome)
TCD4
CPT Codes
86359, 86360
Preferred Specimen
3 mL whole blood in a lavender EDTA tube
Minimum Volume
0.2 mL
Other Acceptable Specimens
Pink EDTA tube
Instructions
Send specimen in original tube. Do not aliquot.
Transport Container
Original tube
Transport Temperature
Ambient
Specimen Stability
Ambient: 72 hours
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis: Reject
Gross lipemia: Reject
Other ACD or heparinized blood, specimen in aliquot tube
Gross lipemia: Reject
Other ACD or heparinized blood, specimen in aliquot tube
Methodology
Flow Cytometry
FDA Status
Approved
Setup Schedule
Monday through Sunday
Report Available
1-2 days
Limitations
T-cell counts should be appropriately interpreted in context of the clinical presentation and other immunological parameters and relevant laboratory test results.
For serial monitoring of T-cell numbers it is recommended that the patient be evaluated at the same time of the day to account for diurnal variation.
For follow-up of infants identified by newborn screening for severe combined immunodeficiency (SCID) and severe T-cell lymphopenia, SCID should be considered as a potential diagnosis in infants with fewer than 300 autologous CD3 T cells/mcL. Infants with 300 to 1500 autologous CD3 T cells/mcL may have leaky SCID, Omenn syndrome, or variant SCID, depending on other clinical and molecular features.
In infants identified by newborn screening for SCID, T-cell lymphopenia is defined as having up to 1500 autologous CD3T cells/mcL.
This assay should not be used for diagnosing T-lymphocytic malignancies or evaluation of T-cell lymphocytosis of unknown etiology, though the latter may be identified through this assay in a screening assessment. In such cases, LCMS / Leukemia/Lymphoma Immunophenotyping, Flow Cytometry, Varies will be recommended, which includes a hematopathology review.
Also, when diagnostically assessing lymphocyte subsets (quantitatively) in any of the above clinical contexts, it may be more useful to order the T-cell, B-cell, and natural killer (NK)-cell quantitation assay rather than the T-cell subset quantitation alone, as it excludes B-and NK-cell counts.
For serial monitoring of T-cell numbers it is recommended that the patient be evaluated at the same time of the day to account for diurnal variation.
For follow-up of infants identified by newborn screening for severe combined immunodeficiency (SCID) and severe T-cell lymphopenia, SCID should be considered as a potential diagnosis in infants with fewer than 300 autologous CD3 T cells/mcL. Infants with 300 to 1500 autologous CD3 T cells/mcL may have leaky SCID, Omenn syndrome, or variant SCID, depending on other clinical and molecular features.
In infants identified by newborn screening for SCID, T-cell lymphopenia is defined as having up to 1500 autologous CD3T cells/mcL.
This assay should not be used for diagnosing T-lymphocytic malignancies or evaluation of T-cell lymphocytosis of unknown etiology, though the latter may be identified through this assay in a screening assessment. In such cases, LCMS / Leukemia/Lymphoma Immunophenotyping, Flow Cytometry, Varies will be recommended, which includes a hematopathology review.
Also, when diagnostically assessing lymphocyte subsets (quantitatively) in any of the above clinical contexts, it may be more useful to order the T-cell, B-cell, and natural killer (NK)-cell quantitation assay rather than the T-cell subset quantitation alone, as it excludes B-and NK-cell counts.
Reference Range
Included with report
Clinical Significance
Serial monitoring of CD4 T cell count in patients who are HIV-positive
Follow-up and diagnostic evaluation of primary cellular immunodeficiencies, including severe combined immunodeficiency
T-cell immune monitoring following immunosuppressive therapy for transplantation, autoimmunity, and other immunological conditions where such treatment is utilized
Assessment of T-cell immune reconstitution post hematopoietic cell transplantation
Early screening of gross quantitative anomalies in T cells in infection or malignancies
Follow-up and diagnostic evaluation of primary cellular immunodeficiencies, including severe combined immunodeficiency
T-cell immune monitoring following immunosuppressive therapy for transplantation, autoimmunity, and other immunological conditions where such treatment is utilized
Assessment of T-cell immune reconstitution post hematopoietic cell transplantation
Early screening of gross quantitative anomalies in T cells in infection or malignancies
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
CD4 Count for Immune Monitoring, Blood
